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Somatic and germline mutations in PTEN (phosphatase and tensin homolog deleted on chromosome 10) are
found in sporadic cancers and Cowden syndrome patients, respectively. Recent identiﬁcation of naturally
occurring cancer and germline mutations within the ATP-binding motifs of PTEN (heretofore referred to as
PTEN ATP-binding mutations) has revealed that these mutations disrupted the subcellular localization and
tumor-suppressor activity of PTEN. However, very little is known about the underlying mechanisms of
PTEN ATP-binding mutations in tumorigenesis. Here we show that these mutations impair PTEN’s function
both qualitatively and quantitatively. On the one hand, PTEN ATP-binding mutants lose their phosphatase
activity and the effect of downregulation of cyclin D1. On the other, the mislocalized mutant PTEN results
in a signiﬁcantly decreased nuclear p53 protein level and transcriptional activity, enhanced production of
reactive oxygen species, induction of Cu/Zn superoxide dismutase as well as dramatically increased DNA
double-strand breaks (DSBs). When compared with wild-type PTEN, the ATP-binding mutant PTEN has
reduced half-life in vitro and decreased protein expression levels in vivo. Our data, thus, reveal a novel mech-
anism of tumorigenesis in patients with germline or somatic mutations affecting PTEN ATP-binding motifs,
i.e. qualitative and quantitative impairment of PTEN due to the loss of its phosphatase activity, and nuclear
mislocalization, resulting in rapid PTEN protein degradation, suppression of p53-mediated transcriptional
activity, loss of protection against oxidative stress as well as accumulation of spontaneous DNA DSBs.
INTRODUCTION
Breast cancer is the most common malignancy and the second
most common cause of cancer-related deaths in women of the
western world with an estimated 192 370 new cases, and
40 170 deaths among US women during 2009 (1). The tumor-
suppressor PTEN (phosphatase and tensin homolog deleted on
chromosome 10) plays an important role in both hereditary
and sporadic breast cancer. Our laboratory ﬁrst reported that
germline mutations in PTEN are associated with Cowden
syndrome (CS) (2) and Bannayan–Ruvalcaba–Riley syndrome
(3),whichconfersahighriskofbreastandothercancers.ForCS
females, the lifetime risk of developing breast cancer is 25–
50%, compared with 13% in the general US population, and at
an average age of diagnosis between 38 and 46 years, compared
with 55–65 years in the general population (4). Furthermore,
somatic loss of PTEN expression and/or function is often
detected in a signiﬁcant fraction of sporadic breast cancers.
Accumulating evidence suggests that the subcellular local-
ization of PTEN may play an important role in cell growth
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not identical to that of cytoplasmic PTEN. Nuclear PTEN
plays a powerful role in regulating chromosome stability by
binding centrosomes (5), DNA repair (6) and cell cycle
arrest (7). There appears to be several mechanisms of PTEN
cytoplasmic-nuclear trafﬁcking. The cytoplasm-predominant
CS mutation (PTEN
K289E) has been reported to disrupt
PTEN ubiquitination and thus abolish its nuclear import (8).
In contrast, we identiﬁed that both ATP depletion and germ-
line or somatic mutations in PTEN’s ATP-binding motifs
(which we will heretofore refer to as PTEN ATP-binding
mutations) result in PTEN subcellular mislocalization which
we hypothesized results in defects in its nuclear export (9,10).
PTEN contains two ATP-binding motifs and both are loca-
lized within its phosphatase domain, with the 3′ one lying
within the phosphatase core motif (residues 60–73; residues
122–136) (9). In contrast to PTEN
WT, both cancer-associated
somatic (PTEN
K62R, PTEN
Y65C and PTEN
K125E) and germline
PTEN missense mutations (PTEN
R130G and PTEN
Y68H), which
lie within the ATP-binding motifs, result in nuclear mislocali-
zation as a cellular phenotypic hallmark (9).
Beyond these observations, little is known about the precise
mechanism of breast carcinogenesis induced by the PTEN
ATP-binding mutations. Therefore, in the present study, we
sought to analyze the functional consequences of nuclear-
cytoplasmic mislocalization of these PTEN ATP-binding
mutants in breast carcinogenesis.
RESULTS
ATP-binding motif mutants abrogate PTEN’s
tumor-suppressive capabilities on cell signaling pathways
To determine the relative contribution of the PTEN ATP-
binding mutations in breast carcinogenesis, we established
clones with stable PTEN expression controlled by a Tet-off
system to examine the consequences of increased levels of
wild-type (WT) and mutant PTEN expression in a well-
characterized breast cancer line, MCF-7, as we described
before (9,11). These naturally occurring mutations derive
from germline and somatic origins. When cultured in the
absence of tetracycline (Tet), transfected PTEN constructs in
all the stable cell lines (PTEN
WT, PTEN
K62R, PTEN
Y65C and
PTEN
K125E) were equally expressed when detected with an
antibody against the FLAG tag in the C-terminal of PTEN
(Fig. 1 and Supplementary Material, Fig. S1). We then deter-
mined the effect of PTEN overexpression on phospho-AKT
(P-AKT) and cyclin D1 levels in unstimulated cells. P-AKT
was selected as a downstream read-out of the PTEN lipid
phosphatase activity; we measured cyclin D1 because it is
an important regulator of G1 to S-phase transition downstream
of PTEN, and especially nuclear PTEN. We found that the
induction of PTEN
WT expression resulted in a signiﬁcant
decrease in the levels of both P-AKT and cyclin D1; in con-
trast, the expression of each of the mutant PTENs was
unable to alter either P-AKT or cyclin D1 levels (Fig. 1).
Together, our results suggest that mutations within ATP-
binding motifs impaired PTEN’s phosphatase activity and
further abolished PTEN’s appropriate regulation of G1/S pro-
gression, as reﬂected by unopposed P-AKT and cyclin D1
signaling pathways. This qualitative impairment of PTEN
function represents at least one of the mechanisms by
which these tumor-derived ATP-binding mutations lead to
carcinogenesis.
Mislocalized PTEN ATP-binding mutants reduce
p53 levels in the nucleus
One of the most important intracellular phenotypic changes of
the MCF-7 stable cell lines and lymphoblastoid cells harboring
patient PTEN ATP-binding mutations is the predominant
nuclear localization, which is accompanied by decreased G1/S
ratio and apoptotic rate when compared with the PTEN
WT
cells (9). In order to investigate the role of the PTEN ATP-
binding mutants in the nucleus, we determined the nuclear
phospho-RB (P-RB) and p53 protein expression levels in
MCF-7 stable cells by subcellular fractionation after 24 h
culture in Tet-free medium. As shown in Figure 2A, a
marked reduction in nuclear p53 levels, accompanied by
increased P-RB levels, was observed in MCF-7 cells over-
expressing K62R, Y65C or K125E mutant PTEN.
To further validate these biochemistry results, we carried
out immunoﬂourescence confocal analyses for nuclear p53
immunostaining intensity in MCF-7 stable cell lines.
Whereas the overexpression of PTEN
WT resulted in an 85%
increase in p53 immunostaining intensity, when compared
with vector-only transfected cells, exogenously expressed
K62R, Y65C and K125E PTEN mutants showed signiﬁcantly
decreased p53 immunostaining intensity when compared with
PTEN
WT (Fig. 2B) (P , 0.001, one-way ANOVA). When
treated with the proteasome inhibitor, MG132, all MCF-7
lines stably transfected with WT or mutant PTEN had
similar levels of p53 protein by immunostaining, suggesting
a post-translational degradation mechanism of p53 in the pres-
ence of the PTEN ATP-binding mutants (Supplementary
Material, Fig. S2) (P . 0.05, one-way ANOVA).
p53 is a transcriptional activator that binds to sequence-
speciﬁc binding sites at the promoters of several cellular
genes and activates their transcription. Recent studies have
indicated that PTEN
WT enhances p53-mediated transactivation
of the promoter by stabilization of p53 in a phosphatase-
independent manner (12). The decreased p53 abundance in
Figure 1. The effects of PTEN
WT and PTEN ATP binding mutants on AKT
phosphorylation and cyclin D1 expression. MCF-7 Tet-off cells were stably
transfected with plasmids encoding pTre2hyg vector only (Vector),
FLAG-PTEN
WT, FLAG-PTEN
K62R, FLAG-PTEN
Y65C and FLAG-
PTEN
K125E. After a 24 h induction in the absence of Tet, whole-cell extracts
were prepared and probed by immunoblotting for P-AKT, AKT, cyclin D1,
FLAG-PTEN and tubulin levels.
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gate the p53-mediated transcriptional activation. A luciferase
reporter that contains p53-speciﬁc binding sites was trans-
fected into MCF-7 stable cells overexpressing PTEN contructs
(WT, K62R, Y65C and K125E) or the empty vector, and the
p53 transcriptional activities were compared through the luci-
ferase assay. As shown in Figure 2D, p53-mediated transcrip-
tion was stimulated the greatest when MCF-7 cells were
overexpressing PTEN
WT (a 3.4-fold increase, when compared
with the empty vector, P , 0.005). All three PTEN ATP-
binding mutants, however, only showed minor increases in
the transcriptional activities (1.4–1.7-fold increase, when
compared with the empty vector, and 1/3–1/2 that of the
WT PTEN context).
To further conﬁrm the decreased transcriptional activity of
p53 in PTEN mutants, we next did a quantitative analysis of
p53-targeted gene expression by real-time quantitative RT–
PCR (qRT–PCR). The mRNA abundance of a p53-inducible
Figure 2. PTEN ATP-binding mutations downregulate p53 in the nucleus. (A) Nuclear (N) and cytoplasmic (C) fractions in the absence of Tet were prepared and
examined for protein levels of p53 and P-RB. The data represent the fold change of the normalized nuclear p53 (p53/PARP-1) and nuclear P-RB (P-PB/PARP-1)
expressed in MCF-7 cells overexpressing the PTEN mutants, compared with those in MCF-7 cells overexpressing PTEN
WT, respectively. (B) p53 protein local-
ization and intensity in MCF-7 cells determined by confocal microscope imaging and immunoﬂuorescence. MCF-7 cells stably transfected with PTEN
WT or
PTEN ATP-binding mutations were ﬁxed and analyzed by immunoﬂuorescence for endogenous p53 protein staining. p53 was detected with a polyclonal anti-
body followed by a goat anti-rabbit secondary antibody conjugated to Alexa Fluor 568 (red). Nuclei were counterstained with DAPI (blue). (C) Quantiﬁcation of
immunoﬂuorescence intensity for p53 in MCF-7 cells overexpressing PTEN
WT and mutants. The data represent the average of three independent measurements.
(D) Luciferase reporter assay. PTEN
WT but not ATP-binding mutants enhances p53 transcriptional activity. MCF-7 cells stably expressing PTEN
WT or PTEN
ATP-binding mutants, as well as the empty vector, were transfected with PG13-luc plasmid. Forty-eight hours later, luciferase activity was measured in cell
lysates using equal amounts of protein. ∗P , 0.005 versus PTEN
WT.( E) Transient transfection of PTEN ATP-binding mutants into HEK293 cells decreases
Bax mRNA transcription. Following transfection with the PTENs or control vector DNA, total RNA was extracted to measure Bax mRNA levels by qRT–
PCR. ∗P , 0.05 versus PTEN
WT.( F) Transient transfection of PTEN ATP-binding mutants into HEK293 cells does not change p53 mRNA transcription.
Total RNA from the above experiment was also used to measure p53 mRNA levels by qRT–PCR (P . 0.05). (G) Total protein lysates were extracted from
MCF-7 cells stably expressing PTEN
WT, K62R, Y65C, K125E or the empty vector. Immunoblots were performed for p53, MDM2, P-MDM2, FLAG and tubulin.
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transfection with each PTEN construct (WT, K62R, Y65C
or K125E) or the empty vector. Consistent with the reduced
p53 levels (Fig. 2A and B) and p53 transcriptional activity,
decreased BAX mRNA levels were observed in HEK293
cells overexpressing PTEN ATP-binding mutations, when
compared with the same cells overexpressing PTEN
WT or
the empty vector (Fig. 2E). p53 mRNA levels, however, did
not show signiﬁcant changes when HEK293 cells were trans-
fected with either PTEN-WT or ATP-binding mutants, which
supports our hypothesis that the diminished p53 protein levels
in these PTEN mutants are due to accelerated post-
translational degradation (Fig. 2F).
We then investigated the post-translational mechanism of
p53 degradation by western blot. We ﬁrst compared the induc-
tion of PTEN and p53 levels in MCF-7 cells overexpressing
PTEN constructs (WT, K62R, Y65C and K125E) in the
absence of Tet (Supplementary Material, Fig. S1). After
removal of Tet for 24 h, expression of the FLAG-tagged
PTEN was similar for all four PTEN constructs. Interestingly,
p53 protein levels increased after removal of Tet only in cells
overexpressing PTEN
WT, suggesting that overexpression of
PTENWT, but not PTEN ATP-binding mutants, can increase
p53 protein levels. We then compared MDM2 and
phospho-MDM2 (P-MDM2) levels in the MCF-7 cell lines
stably transfected with each construct, with the rationale that
PTEN can stabilize p53 through the degradation of MDM2
by the suppression of the PI3K pathway. Surprisingly, we
observed increased MDM2/P-MDM2 in cells overexpressing
PTEN
WT and decreased MDM2/P-MDM2 in cells overexpres-
sing each PTEN ATP-binding mutant (Fig. 2G). This may
reﬂect a possible feedback mechanism in which the mutant
cells produce MDM2/P-MDM2 in an attempt to rescue p53
from further degradation. It also suggests that the degradation
of p53 in the PTEN ATP-binding mutants is MDM2-
independent. Taken together, our data suggest that the PTEN
ATP-binding mutants are unable to stabilize p53 in the
nucleus and may even induce p53 inactivation through
enhanced MDM2-independent degradation and decreased
transcriptional activity.
PTEN ATP-binding mutations cause accumulated
DNA double-strand breaks
The predominant nuclear localization of the PTEN ATP-
binding mutations prompted us to hypothesize that these
mutations may disrupt chromosomal integrity by inducing
double-strand breaks (DSBs) via a mechanism beyond dis-
rupting binding to centrosomes. To test this, we detected
g-H2AX by immunoﬂuorescence microscopy in senile
MCF-7 cells (at passage 40 for all cell lines). After DNA
DSBs, histone H2AX is rapidly phosphorylated on serine
139, referred to as g-H2AX which is emerging as an impor-
tant marker of DSBs (13).
As expected, overexpression of PTEN
WT in MCF-7 cells
did not change the intensity of g-H2AX staining, when
compared with cells transfected with vector control (Fig. 3A
and B). In contrast, MCF-7 cells overexpressing the
cancer-associated PTEN mutants, K62R, Y65C or K125E
had g-H2AX intensity much higher than that of the vector
only control. More importantly, the increased intensity for
g-H2AX was not found in the earlier passage (,10) cells
(data not shown). This suggests that DSBs accumulate in the
Figure 3. PTEN ATP-binding mutations lead to increased DSBs. (A) MCF-7
cells stably expressing PTEN
WT or PTEN ATP-binding mutants were ﬁxed
and immunostained for g-H2AX (green). The cells were counterstained
with DAPI (blue). (B) Statistical analysis of the g-H2AX ﬂuorescence data.
∗P , 0.001 versus PTEN
WT.
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toward senescence, at least in vitro.
Breast cancer cells overexpressing PTEN ATP-binding
mutations are under oxidative stress
It is well documented that reactive oxygen species (ROS)
represents one mechanism whereby stress-induced senes-
cence results from ROS-associated DSBs. Based on the
observation of the increased DSBs in senescent (operation-
ally deﬁned as .40 passage cells) MCF-7 cells overexpres-
sing the PTEN ATP-binding mutations, we next examined
the basal levels of ROS production in the ﬁve MCF-7
stable cell lines. Cells overexpressing PTEN
WT had a
lower level of ROS production compared with control
cells expressing empty vector, when not stimulated. In con-
trast, signiﬁcantly activated ROS was observed in cells
overexpressing PTEN
K62R, PTEN
Y65C and PTEN
K125E
(Fig. 4A and B). We then detected the quantity of Cu/
Zn-SOD (SOD1) by western blot in the same cell lines.
Elevated SOD1 levels were detected in cells overexpressing
PTEN
K62R, PTEN
Y65C and PTEN
K125E (Fig. 4C). Thus, the
PTEN ATP-binding mutations lead to increased oxidative
stress, characterized by enhanced ROS production and aber-
rant expression of the antioxidative enzyme, SOD1.
Because tumor protein 53-induced nuclear protein 1
(TP53INP1) is a major mediator of p53 antioxidant function,
we further compared TP53INP1 mRNA levels in MCF-7
cell lines expressing the FLAG-tagged PTEN (WT and
mutants) by qRT–PCR (14). MCF7 cells overexpressing any
of the mutant PTEN constructs exhibited a decreased level
of TP53INP1 mRNA when compared with those expressing
PTEN
WT (Fig. 4D). This observation is consistent with the
decreased p53 protein levels, reduced p53 transcriptional
activity and increased ROS in cells overexpressing PTEN
ATP-binding mutants.
Figure 4. PTEN ATP-binding mutations increase ROS production and SOD1 expression. (A) MCF-7 cells stably expressing empty vector, PTEN
WT or PTEN
ATP binding mutants were incubated with 25 mM Carboxy-H2DCFDA for 30 min and immunoﬂuorescent images were taken for ROS production (green). DNA
was counterstained with Hoechst 33342 (blue). (B) Quantitation of immunoﬂuorescence intensity of DCF [from (A)] in MCF-7 cells overexpressing PTEN
WT
and mutants. The data represent the average of three independent measurements. P , 0.01, one-way ANOVA. (C) SOD1 protein was detected in cell lines
expressing WT or mutant PTEN by western blot. (D) Total RNA from MCF-7 cells overexpressing WT or mutant PTEN was extracted and qRT–PCR was
performed to measure TP53INP1 mRNA levels. P , 0.01, one-way ANOVA.
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We then examined PTEN stability through pulse-chase
experiments using cycloheximide (CHX). We found a sig-
niﬁcant reduction in the half-lives of PTEN
K62R but not
PTEN
Y65C or PTEN
K125E proteins, when compared with
PTEN
WT (Fig. 5A and B). We then compared the endogen-
ous PTEN levels in lymphoblastoid cells isolated from two
CS patients harboring germline heterozygous PTEN ATP-
binding mutations (Y68H and R130G) and from two
normal WT controls. Signiﬁcantly reduced PTEN levels
were detected in both CS patients when compared with
those in the WT controls (Fig. 5C). These results suggest
that some PTEN ATP-binding mutant proteins are unstable
proteins which may be degraded.
To determine whether the instability of the K62R mutant
protein is through proteasomal degradation, we transfected a
PTEN null breast cancer cell line, BT-549, with FLAG-tagged
PTEN
K62R and treated with CHX for 16 h in the presence or
absence of MG132. Treatment of BT-549 cells alone with
100 mg/ml CHX reduced PTEN
K62R protein levels to less
than 20% of the untreated levels (Fig. 5D, lane 2). In the pres-
ence of the proteasome inhibitor MG132, however, PTEN
K62R
was substantially stabilized (Fig. 5D, lane 3). We therefore
conclude that the instability of PTEN
K62R is mediated by
enhanced proteasomal degradation.
DISCUSSION
We have previously shown that PTEN ATP-binding motif
mutations alter cellular proliferation, apoptosis and anchorage-
dependent growth (9). Our results here demonstrate that PTEN
ATP-binding mutations can lead to both qualitative and quan-
titative impairment of the tumor-suppressive function of
PTEN. Mutations within the ATP-binding motifs not only
change PTEN subcellular localization, but also lead to deregu-
lated PTEN expression and activity.
The phosphatase activity of PTEN is important to its role in
cell cycle arrest. Our current experiments show that all three
ATP-binding motif mutations have abrogated phosphatase
activity accompanied by unchanged cyclin D1 levels. Consid-
ering both ATP-binding motifs are located within the phospha-
tase domain of PTEN (residues 1–185), especially for
PTEN
K125E, which is located within the catalytic core motif
of PTEN (HCXXGXXR; residues 123–130), it is reasonable
to postulate that these mutations impair PTEN’s phosphatase
activity and thus diminish PTEN’s tumor-suppressive
function (15).
The human breast carcinoma MCF-7 cell line was the main
cell line used in our in vitro studies. We chose the MCF-7 cell
line (which contains both WT PTEN and WT p53) for two
major reasons: (i) we wanted to further investigate the inter-
play between nuclear PTEN and p53 in breast cancer cells
Figure 5. PTEN ATP-binding mutations reduce protein stability. (A) CHX-chase analyses of PTEN degradation in MCF-7 cells overexpressing WT or mutant
PTEN. Cells were incubated with CHX (50 mg/ml) and were harvested at the indicated time points. Whole protein lysates were harvested and ran for western
blots using anti-FLAG antibody for transfectant PTEN and anti-tubulin antibody as a loading control. (B) Protein half-lives of PTEN
WT, PTEN
K62R, PTEN
Y65C
and PTEN
K125E. Linear plots represent the averages range of two independent experiments. (C) Western blots of whole cell lysates derived from lyphoblastoid
cells isolated from two CS patients with indicated genotypes (PTEN
Y68H/WT and PTEN
R130G/WT) as well as two normal WT controls. (D) Proteasomal degra-
dation of PTEN
K62R. PTEN null BT-549 cells were transfected with FLAG-tagged PTEN
K62R and were treated with either DMSO, CHX (50 mg/ml) or a com-
bination of CHX and MG132 (10 mM) for 16 h. Exogenously expressed PTEN protein levels were determined by western blot using an anti-FLAG antibody. (E)
Model for tumorigenesis induced by PTEN ATP-binding mutations. Mutations within PTEN ATP-binding motifs lead to PTEN nuclear mislocalization and
decreased p53 level through an MDM2-independent way. Impaired activities of PTEN and p53will increase the vulnerability of cells to oxidative stress, as pre-
sented by enhanced ROS, upregulated SOD1 and DNA damage. Loss of phosphatase activities in the PTEN ATP-binding mutants, together with p53 deactiva-
tion, can lead to the loss of G1/S checkpoint, as presented with abnormal cell proliferation and survival. For the mutant such as K62R, it undergoes proteasomal
degradation. All these quantitative and qualitative impairments compromise PTEN’s tumor-suppressor activity.
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mutant PTEN in a heterozygous state that mimics the in vivo
situation in CS breast cancer and sporadic primary breast car-
cinomas (16). PTEN has been reported to upregulate p53
protein levels and transcriptional activity. In the nucleus,
PTEN physically interacts with p53 through its C2 domain
and forms a PTEN/p53 complex to stabilize the latter (17).
Because the ATP-binding mutations are within PTEN’s phos-
phatase domain instead of its C2 domain, it is unlikely that this
effect is through the disruption of direct binding between
PTEN and p53 in the nucleus.
One of the main pathways for p53 degradation is through
MDM2-induced ubiquitination. In our study, however, a sig-
niﬁcant decrease in the P-MDM2 signal was observed in
MCF-7 cells with ectopic expression of the PTEN ATP-
binding mutants, suggesting that the downregulation of p53
in the ATP-binding mutants may be mediated via a
phosphatase-independent and MDM2-independent manner.
In the nucleus, PTEN can form a complex with p300 and
plays a role in maintenance of high p53 acetylation, which
is important in the control of p53 protein stability and DNA
binding (18,19). The accumulated PTEN ATP-binding
mutants in the nucleus may interfere with PTENWT forming
a complex with p300 for p53 acetylation, and therefore redu-
cing both the stability and the transcriptional activity of p53.
Further detailed work will be required in the future to eluci-
date the precise mechanism of how PTEN ATP-binding
mutations/mutants participate in the downregulation of p53
in the nucleus.
As a transcription factor, p53 regulates genes involving
apoptosis, cell cycle and oxidative stress. In agreement with
the reduced p53 protein levels, repressed p53 transcriptional
activity was demonstrated by luciferase assay in cells overex-
pressing PTEN mutants. Also consistent, we found that tran-
script levels of a key downstream effector of p53, BAX,
were signiﬁcantly suppressed in the context of PTEN ATP-
binding mutants. Loss of BAX transcription likely boosts pro-
liferative and survival signals consistent with our previously
published data (9). All in all, this may suggest a ﬁne balance
of nuclear PTEN and p53 and that the regulation of this
balance is important for normal cell function (Fig. 5E).
The balance of nuclear to cytoplasmic PTEN is important
for its tumor-suppressor function. PTEN must associate with
the plasma membrane to maintain appropriate steady-state
levels of phosphatidylinositol 3,4,5-triphosphate (20,21). At
the same time, nuclear PTEN is a key factor for proper cell
cycling and chromosomal integrity. Shen et al.( 5) reported
increased spontaneous DNA DSBs in Pten-deleted mouse
embryonic ﬁbroblasts. They also found that a protein from a
CS patient with a PTEN R189X mutation does not bind to
CENP-C, indicating that PTEN associates with CENP-C in a
phosphatase-independent manner (through its C-terminal).
These observations together suggest that PTEN’s C-terminal
domain associates with centrosome proteins to maintain
chromosome integrity.
Similar to their results, in our study, we found that MCF-7
cells overexpressing PTEN ATP-binding mutations exhibited
spontaneous DNA DSBs. Because all three analyzed
mutations contain an intact C-terminal of PTEN, it is unlikely
that the spontaneous DNA DSBs caused by these mutations
are due to the loss of binding between the mutant PTEN and
CENP-C.
Unlike the previous observations, in our study, the DSBs
only accumulate with aging of the cells. Oxidative stress
plays an important role in breast tumorigenesis through pro-
moting the survival of mammary tumor cells and inducing
DNA damages (22,23). ROS is involved in the pathogenesis
of aging and cancer, and the escalated ROS generation pro-
vides an endogenous source of DNA-damaging agents that
promote genetic instability (24). PTEN deletion has been
reported to be a key player in ROS-induced oxidative
damage of DNA (25). Notably, unlike PTEN
WT, PTEN-
containing ATP-binding mutations are unable to inhibit ROS
production, as presented by signiﬁcantly higher ROS acti-
vation (Fig. 4) and consequent elevation of SOD1, suggesting
that their anti-oxidative abilities are impaired.
p53 protects the genome from oxidation by ROS through
the upregulation of several genes with antioxidant products,
associated with a decrease in intracellular ROS (26). The
downregulation of p53 results in an increase in intracellular
ROS and excessive oxidation of DNA, increased mutation
rate and genomic instability (27). TP53INP1 is a major
player in p53-driven oxidative stress response (14). Our obser-
vation that cells overexpressing PTEN with ATP-binding
mutations have decreased p53 protein levels, impaired p53
transcriptional activity and reduced TP53INP1 transcription
is consistent with the hypothesis that such mutations result
in loss of PTEN’s protective effect against ROS-induced oxi-
dative damage, at least as cells age, and therefore may contrib-
ute to the oxidative damage of DNA in that setting.
PTEN stability is regulated by ubiquitination, oxidation and
phosphorylation (28). In our study we found PTEN
K62R is
unstable, and we also found patients harboring germline
mutation of PTEN
Y68H and PTEN
R130G have decreased
PTEN protein levels than the WT controls. Our experiment
conﬁrmed that PTENK62R is degraded mainly through the
proteasome pathway which underlines the quantitative impair-
ment of the ATP-binding mutations of PTEN.
Our ﬁndings therefore beg one question: do these three
mutations (K62R, Y65C and K125E) and their consequences
promote breast tumorigenesis? K125E, lying within ATP-
binding motif B (residues 122–136), is within the core cataly-
tic domain of PTEN (residues 124–129), and it is only one
amino acid away from the important C124 residue which
confers PTEN’s lipid and protein phosphatase activities. We
found that K125E mutant cells have the most robust prolifer-
ation (9), fastest clonogenic formation ability (9) and the
lowest p53 transcriptional activity (as presented by the lucifer-
ase assay and BAX mRNA levels; Fig. 2). In contrast, K62R
and Y65C, both located within the ATP-binding motif A (resi-
dues 60–73), appear to behave more similar to each other than
to K125E. K125E is almost certainly exerting its effect in at
least a dual manner: as a phosphatase dead (most likely) trap-
ping mutant (dominant negative) and by nuclear mislocaliza-
tion. We therefore believe that the effect of these ATP motif
mutants is an end result of a balance between quantitative
(dosage effect) and qualititative (e.g. mislocalization, phos-
phatase affected, etc.) problems.
In conclusion, we provide evidence that a mechanism for
tumorigenesis of cells harboring germline or somatic
86 Human Molecular Genetics, 2011, Vol. 20, No. 1mutations within PTEN ATP-binding motifs is through the
quantitative and qualitative impairment of PTEN tumor-
suppressor function. Moreover, our study provides novel
insights on oxidative stress which may contribute to breast car-
cinogenesis in patients with germline or somatic PTEN
mutations that result in PTEN nuclear predominance and
may help explain why cells become more susceptible to
cancer by accumulating DSBs due to loss of PTEN protection
against ROS with age. In addition, targeting oxidative stress
may help in the development of a therapeutic strategy for
patients harboring such mutations or mutations with similar
functional effects.
MATERIALS AND METHODS
Cell culture
Tet-off stable MCF-7 cell lines overexpressing FLAG-tagged
PTEN (FLAG-PTEN
WT, FLAG-PTEN
K62R, FLAG-PTEN
Y65C
and FLAG-PTEN
K125E) were obtained as previously described
(9). Tet-off stable MCF-7 cells were grown in DMEM sup-
plemented with 10% fetal bovine serum and 1 mg/ml Tet.
Before harvest, MCF-7 stable cells were treated with media in
the absence of Tet for 24 h in order to induce overexpression
of the transfected PTEN. Immortalized lymphoblastoid cells
obtained from CS patients or normal controls were grown in
RPMI 1640 supplemented with 10% fetal bovine serum.
Patients
Diagnosis of CS was according to the International Cowden
Syndrome Consortium (29). We utilized peripheral blood
samples from two CS patients with germline mutations in the
ATP-bindingdomainofPTEN(Y68HandR130G).Wealsouti-
lized peripheral blood samples from two normal WT controls.
Informed consent was obtained from all subjects (CS individ-
uals and controls) in accordance with procedures and protocols
approvedbytherespectiveHumanSubjectsProtectionCommit-
tee of each participating institution. All subjects, whether CS or
controls, participated on a voluntary (unpaid) basis.
Protein isolation, SDS–PAGE and western blot analyses
For whole cell protein lysates, cells were washed twice with
ice-cold PBS and were harvested in M-PER buffer (Pierce,
Rockford, IL, USA) with protease inhibitors and phosphatase
inhibitors. After quantitation, proteins were run on 4–15%
SDS–PAGE gels and transferred to nitrocellulose. Blots
were probed with primary antibodies and followed by incu-
bation with secondary antibody and then visualized using
enhanced chemiluminescence detection. The antibodies for
cyclin D1, SOD1, P-AKT (Ser473), AKT, P-MDM2
(Ser166) and p53 were obtained from Cell Signaling Technol-
ogy (Danvers, MA, USA). PTEN antibody was from Cascade
Biosciences (Winchester, MA, USA).
Subcellular fractionation
For the nuclear and cytoplasmic fractionation, cells were har-
vested by trypsinization and then were incubated with buffer A
(10 mM MOPS, 1.5 mM MgCl2,1 0 m M KCl and 1% Triton
X-100) for 15 min on ice with vortex for every 5 min. Cells
were then centrifuged at 12 000g for 5 min at 48C and the
supernatant was carefully collected as the cytoplasmic frac-
tion. The pellets were then incubated with buffer A for
another 15 min and separated by centrifugation at 12 000g
for 5 min at 48C. The pellets were dissolved in RIPA buffer.
The purity of each fraction was analyzed by immunoblotting
using antibodies against a-tubulin (Sigma Aldrich, St Louis,
MO, USA) for the cytoplasm and PARP-1 (Santa Cruz, CA,
USA) for the nucleus.
Indirect immunoﬂuorescence and confocal microscopy
Cells were seeded insix-well plates withcoverslips. Cells were
ﬁxed in a freshly prepared 100% methanol for 1 min at 2208C.
After 5 min incubation with 0.3% Triton X-100 in PBS, the
cover slips were washed three times in PBS, blocked in PBS
with 10% goat serum for 30 min, incubated with primary anti-
bodies for 1 h, washed three times in PBS and ﬁnally incubated
with Alexa Fluor
w dye-labeled secondary antibodies for 1 h at
the concentration of 1:1000 (Invitrogen, Carlsbad, CA, USA).
The immunoﬂuorescence antibodies were purchased and used
as follows: FLAG M2 monoclonal antibody from Sigma
Aldrich (Cat# F1804, 1:300 dilution), p53 rabbit antibody
from Cell Signaling (Cat#9282, 1:50 dilution), g-H2AX (Cat#
05–636; Upstate Biotechnology, Charlottesville, VA, USA,
1:800 dilution). Cells were mounted on glass slides with Pro-
Long
w Gold antifade reagent with DAPI (Invitrogen) and visu-
alized on a Leica TCS-SP spectral laser scanning confocal
microscope as described previously (9). For quantitation of
the immunostaining intensity of p53 in MCF-7 cells, regions
of interest were deﬁned so that they would ﬁt in all nuclei,
and the intensity was measured for all the individual regions
of interest, using the Leica confocal image analysis software.
At least 100 cells, from at least two different slides, were
used for quantitation.
p53 luciferase assay
The PG13-luc plasmid, which contains a p53 reporter with a
ﬁreﬂy luciferase gene under the control of 13 p53 response
elements, was a kind gift from Dr Bert Vogelstein (30)
(Addgene plasmid 16442). MCF-7 stable cells (Vector, WT,
K62R, Y65C and K125E) were plated at 0.5 × 10
6 cells/
60 mm dish and grew overnight before transfection.
PG13-luc plasmid was transfected for 48 h followed by the
Renilla luciferase assays according to the manufacturer’s
instruction (Promega, Cat#E2810). Luciferase activities were
normalized to Renilla control activities.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from HEK293 transiently trans-
fected or MCF7 stably transfected cells using RNeasy
w Mini
Kit (QIAGEN, Inc., Valencia, CA, USA) according to the
manufacturer’s protocol, and subsequently treated with
DNase I (Invitrogen). DNase-treated total RNA was reverse-
transcribed into cDNA using random primers and Super-
TranscriptTM III Reverse Transcriptase (Invitrogen), as
Human Molecular Genetics, 2011, Vol. 20, No. 1 87speciﬁed by the manufacturer. Polymerase chain reaction was
performed using SYBR Green PCR Master Mix and run on
7500 Real Time PCR machine (Applied Biosystem,
Carlsbad, CA). Primer sequences are listed in Table S1,
Supplementary Material. The relative mRNA amounts were
determined by normalizing each set of samples using the
difference in threshold cycles (DCT) between interested
genes and GAPDH as reference gene (DCTSamples ¼
DCTinterested 2 DCTGAPDH).
Fluorescence analysis of ROS
The measurement of ROS in live cells was performed using the
image-iTTM LIVE Green ROS Detection Kit according to the
manufacturer’s instructions (Cat# I36007; Molecular Probes,
Invitrogen). This assay is based on the ﬁnding that oxidation
of the non-ﬂuorescent carboxy-dichlorodihydroﬂuorescein
diacetate (Carboxy-H2DCFDA) by ROS can convert it to the
ﬂuorescent dichloroﬂuorescein (DCF) (31). Brieﬂy, MCF-7
stable cells were incubated with 25 mM Carboxy-H2DCFDA
for 30 min at 378C, and the ﬂuorescence intensity of DCF is
proportional to the ROS activity. Nuclei were counterstained
with Hoechst 33342 and the percentage of ROS-positive
cells/total cells of each cell line was compared.
Statistical analysis
The immunostaining intensity of p53 was compared by
one-way ANOVA. P , 0.05 was considered statistically sig-
niﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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